Abstract:Abstract Background We studied to what extent the level of scientific knowledge on exceptionally rare metabolic inherited diseases and their potential orphan medicinal products is associated with sponsors deciding to apply for an orphan designation at the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Methods All metabolic diseases with a genetic cause and prevalence of less than 10 patients per 1 million of the population were selected from the ‘Orphanet database of Rare diseases’. The outcome of interest was the application for an orphan designation at FDA or EMA. The level of publicly available knowledge of the disease and drug candidate before an orphan designation application was defined as whether the physiological function corresponding with the pathologic gene and initiation of the pathophysiological pathway was known, whether an appropriate animal study was identified for the disease, whether preclinical proof of concept was ascertained and the availability of data in humans. Other determinants included in the study were metabolic disease class, the prevalence of the disease, prognosis and time of first description of the disease in the literature. Univariate relative risks (RRs) and 95% confidence intervals (CIs) of an orphan designation application were calculated for each of these determinants. In addition, a multivariate Cox regression analysis was conducted (Forward LR). Results In total, 166 rare metabolic genetic diseases were identified and included in the analysis. For only 42 (25%) of the diseases an orphan designation application was submitted at either FDA or EMA before January 2012. The multivariate analysis identified preclinical proof of concept of a potential medicinal product as major knowledge related determinant associated with an orphan designation application (RRadj 3.9, 95% CI 1.9-8.3) and confirmed that prevalence of the disease is also associated with filing an application for an orphan designation (RRadj 2.8, 95% CI 1.4-5.4). Conclusion For only one out of four known exceptionally rare metabolic inherited diseases sponsors applied for an orphan designation at FDA or EMA. These applications were found to be associated with the prevalence of the rare disease and the level of available scientific knowledge on the proof of concept linking possible drug candidates to the disease of interest.

Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases

Novel Design and Analysis for Rare Disease Drug Development

Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective

Quantitative Systems Pharmacology Models: Potential Tools for Advancing Drug Development for Rare Diseases

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Human-induced Pluripotent Stem Cells As Models for Rare Cardiovascular Diseases: from Evidence-Based Medicine to Precision Medicine

Challenges of developing and conducting clinical trials in rare disorders

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Natural History and Real‐World Data in Rare Diseases: Applications, Limitations, and Future Perspectives

Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases

Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future

The Role of Pharmacogenomics in Rare Diseases

Exploration of pharmaceutical service model in multidisciplinary diagnosis and treatment of rare diseases in children

Pharmaceutical policy and innovation for rare diseases: A narrative review

Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group

Drug development for exceptionally rare metabolic diseases: challenging but not impossible

Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies

Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making